101 related articles for article (PubMed ID: 9212679)
1. [Effectiveness of prolonged oral therapy with low-dose etoposide in patients aged 85 years and over with non-Hodgkin's lymphoma].
Niitsu N; Nakayama M; Umeda M
Nihon Ronen Igakkai Zasshi; 1997 Apr; 34(4):263-6. PubMed ID: 9212679
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Am J Clin Oncol; 1997 Jun; 20(3):311-4. PubMed ID: 9167761
[TBL] [Abstract][Full Text] [Related]
3. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Haim N; Ben-Shahar M; Epelbaum R
Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
[TBL] [Abstract][Full Text] [Related]
4. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Shaklai S; Bairey O; Blickstein D; Prokocimer M; Hadar H; Lahav M; Sulkes J; Shaklai M
Cancer; 1996 Jun; 77(11):2313-7. PubMed ID: 8635101
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
6. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
Copelan EA; Ceselski SK; Ezzone SA; Lasky LC; Penza SL; Bechtel TP; Klein JL; Hehmeyer DM; Scholl MD; Marshall DD; Elder PJ; Risley GL; Avalos BR
J Clin Oncol; 1997 Feb; 15(2):759-65. PubMed ID: 9053502
[TBL] [Abstract][Full Text] [Related]
7. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
[TBL] [Abstract][Full Text] [Related]
8. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient.
el-Yazigi A; Ezzat A; Berry J; Raines DA; Yusuf A; al-Rawithi S; Legayada ES
J Clin Pharmacol; 2000 Feb; 40(2):153-60. PubMed ID: 10664921
[TBL] [Abstract][Full Text] [Related]
9. [A case of leukemic lymphoma complicated by M-proteinemia: effectiveness of long-term daily administration of oral low-dose etoposide in continuing remission].
Gohda T; Nakano H; Yagi H; Amano I; Tsukaguchi N; Shimoyama T; Morii T; Nishikawa K; Narita N
Gan To Kagaku Ryoho; 1999 Apr; 26(5):703-7. PubMed ID: 10234304
[TBL] [Abstract][Full Text] [Related]
10. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
[TBL] [Abstract][Full Text] [Related]
11. [Etoposide 21 therapy for malignant lymphoma].
Masaoka T
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1936-40. PubMed ID: 8978801
[TBL] [Abstract][Full Text] [Related]
12. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
13. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cytosine arabinoside, carboplatin and etoposide chemotherapy in the treatment of relapsing and refractory non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Acta Haematol; 1996; 96(1):36-40. PubMed ID: 8677759
[TBL] [Abstract][Full Text] [Related]
16. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
17. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Haim N; Ben-Shahar M; Faraggi D; Tsuri-Etzioni A; Leviov M; Epelbaum R
Cancer; 1997 Nov; 80(10):1989-96. PubMed ID: 9366303
[TBL] [Abstract][Full Text] [Related]
19. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
[TBL] [Abstract][Full Text] [Related]
20. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]